Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis.
about
Optimizing treatment success in multiple sclerosisImaging as an Outcome Measure in Multiple Sclerosis.Outcome Measures in Clinical Trials for Multiple Sclerosis.Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies.High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study.A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis.Spinal Cord as an Adjunct to Brain Magnetic Resonance Imaging in Defining "No Evidence of Disease Activity" in Multiple Sclerosis.The Efficacy of Natalizumab versus Fingolimod for Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review, Indirect Evidence from Randomized Placebo-Controlled Trials and Meta-Analysis of Observational Head-to-Head Trials.A regional consensus recommendation on brain atrophy as an outcome measure in multiple sclerosis.Effect of Fingolimod on Brain Volume Loss in Patients with Multiple Sclerosis.Defining Disease Activity and Response to Therapy in MS.MRI in the assessment and monitoring of multiple sclerosis: an update on best practice.Long-term evolution of multiple sclerosis disability in the treatment era.Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosis.Peripheral blood lymphocytes immunophenotyping predicts disease activity in clinically isolated syndrome patients.Assessing Repair in Multiple Sclerosis: Outcomes for Phase II Clinical Trials.Therapeutic Targets for Multiple Sclerosis: Current Treatment Goals and Future Directions.A Novel Semiautomated Pipeline to Measure Brain Atrophy and Lesion Burden in Multiple Sclerosis: A Long-Term Comparative Study.No evidence of disease activity in multiple sclerosis patients.Optimization and stratification of multiple sclerosis treatment in fast developing economic countries: a perspective from Qatar.Treatment decisions in multiple sclerosis - insights from real-world observational studies.Critical analysis on the present methods for brain volume measurements in multiple sclerosis.Comparison of efficacy and safety of oral agents for the treatment of relapsing-remitting multiple sclerosis."No evident disease activity": The use of combined assessments in the management of patients with multiple sclerosis.Loss of corticospinal tract integrity in early MS disease stages.The Evaluation of Oxidative Stress Parameters in Serum Patients with Relapsing-Remitting Multiple Sclerosis Treated with II-Line Immunomodulatory Therapy.SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts.Validating the use of brain volume cutoffs to identify clinically relevant atrophy in RRMS.Management of pregnancy-related issues in multiple sclerosis patients: the need for an interdisciplinary approach.Cell-based therapeutic strategies for multiple sclerosis.Pathological cut-offs of global and regional brain volume loss in multiple sclerosis.Advancing trial design in progressive multiple sclerosis.Defining brain volume cutoffs to identify clinically relevant atrophy in RRMS.A Fully Automated Pipeline for Normative Atrophy in Patients with Neurodegenerative Disease.Nerve Ultrasound Predicts Treatment Response in Chronic Inflammatory Demyelinating Polyradiculoneuropathy-a Prospective Follow-Up.No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study."No evidence of disease activity" - is it an appropriate surrogate in multiple sclerosis?No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a.Establishing pathological cut-offs for lateral ventricular volume expansion rates.Peginterferon β-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing-remitting multiple sclerosis
P2860
Q26771968-CC6855C3-E050-46F6-BAEE-6DDE2F5510DDQ31134617-76E429A0-9081-4C7F-9C97-D2C693614E3FQ31160866-B1391BD3-9971-4D08-ACDB-1DC24EBF7F33Q33628626-8CFF8593-392B-4231-B078-93AE4D5CCF3EQ33736193-84EEE5A8-3BAD-4D24-BC14-4458785BDB6CQ33742905-7EFAE5C1-2AA3-47A0-8805-E79AC801782BQ33769234-8C400EA0-3DF4-4745-8FFB-F28A7EC70DEEQ36148189-9E571314-9982-48D3-AEC9-78EE04930055Q36202826-F011A20B-8086-4FE3-89FF-CAC042F8FA87Q36293431-FA544CA3-7114-4E4C-81A0-9EEEC1F958ACQ36357501-E6506E48-D770-4D7E-9E1C-514D96752101Q36400004-4542460E-0136-4EEC-B661-86A2684CB5C2Q37409279-4B239A00-B2EF-45D9-A259-299A3318B574Q38606914-39E8F802-564F-4A06-91F9-719DF8EA726BQ38654791-F40E4CD6-B13B-41C0-A261-9E84E88691F7Q38659598-66FCAB33-69DF-4326-8AEF-65E63B8FFD92Q38666303-CD3D3132-BE80-4E1F-A0DF-C183F16AD9E1Q38808604-B6BDD64B-C7B3-4341-A59B-EE90DE303BCBQ38879765-F7651573-82FF-4869-8BB9-848EB3B07F1FQ39021942-AAD0F70F-4F12-490D-B2A2-7669ADB003F4Q39022643-BE02520B-4D54-45EB-8B9F-120E0BB7F234Q39459514-44649959-2755-4B03-8F24-872DB416C878Q40090879-41278C63-88EC-4E7F-9533-B2F897854E99Q41185260-9B4D2F71-0013-4982-80BD-0FB5A8E0E751Q41676647-79637654-F2E3-47D3-9BB4-CDE83A07382AQ43375909-B367AAAE-3ECF-4BE8-847B-EF236E4D5ADAQ46861116-3A8AA9B2-5B72-4F4D-B2C6-0EDE7B0876E1Q47445376-A52E463B-0915-4E7A-9375-D1C9C5786EE3Q47678330-1FB8210A-D516-4F83-A09D-B27C51E16025Q47885870-BC93CFDB-439E-462B-AC93-58659B741CDCQ47967210-CA49694E-C0F6-4290-9166-CA340735A95FQ48571910-D8ECFBD2-73D1-4D8F-893B-38E66BE7F132Q48625365-E52C62D4-8D6D-420E-AB36-51A4208465D7Q49247807-689FFBC3-6805-4775-A7C7-D69C2E19FDEDQ50050892-6B929DE9-9FD6-4619-B31B-A241C4F1C990Q50956425-5DAB996E-80A6-4944-AB37-49632407D777Q52567799-E5404A57-0FB1-48CF-AEEC-FB52AD87C0D1Q52641471-6B0656CE-0B3B-4ABA-95A7-4D344A763390Q52661563-4E772D6B-1FE6-4DA1-8FF4-A0D2EEE22E83Q57039929-E01ADDF2-351C-4FBD-82D8-5D29DA385B53
P2860
Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Inclusion of brain volume loss ...... -remitting multiple sclerosis.
@ast
Inclusion of brain volume loss ...... -remitting multiple sclerosis.
@en
type
label
Inclusion of brain volume loss ...... -remitting multiple sclerosis.
@ast
Inclusion of brain volume loss ...... -remitting multiple sclerosis.
@en
prefLabel
Inclusion of brain volume loss ...... -remitting multiple sclerosis.
@ast
Inclusion of brain volume loss ...... -remitting multiple sclerosis.
@en
P2093
P2860
P50
P356
P1476
Inclusion of brain volume loss ...... -remitting multiple sclerosis.
@en
P2093
Bruce Ac Cree
Daniela Piani Meier
Davorka Tomic
Dieter A Häring
Ernst-Wilhelm Radue
Ludwig Kappos
Mark S Freedman
P2860
P304
P356
10.1177/1352458515616701
P577
2015-11-19T00:00:00Z